[Skip to Content]
[Skip to Content Landing]
Article
August 9, 1985

Probable Efficacy of High-Dose Salicylates in Reducing Coronary Involvement in Kawasaki Disease

Author Affiliations

From the Divisions of Clinical Pharmacology (Dr Koren), Cardiology (Drs Rose and Rowe), and Immunology and Rheumatology (Dr Lavi), Department of Pediatrics, and The Research Institute (Dr Koren), The Hospital for Sick Children, and the Departments of Pharmacology (Dr Koren) and Pediatrics (Drs Koren, Rose, Lavi, and Rowe), University of Toronto.

JAMA. 1985;254(6):767-769. doi:10.1001/jama.1985.03360060069027
Abstract

The efficacy of high-dose salicylates in reducing the coronary artery involvement of Kawasaki disease was compared in 36 children who received acetylsalicylic acid, 80 to 180 mg/kg/day, and in 18 who did not receive high-dose salicylates during the febrile phase of the disease and whose fever was controlled mainly with acetaminophen. The two groups were comparable with respect to age and body weight. In the acetylsalicylic acid—treated group, the dose was adjusted to meet the therapeutic serum concentration range (≥20 mg/dL). There were significantly more cases of coronary involvement in the nontreated group (50%) than in the salicylate-treated group (16.6%) and of coronary aneurysms (39% vs 3%). During the febrile phase of the disease, salicylate serum concentrations achieved with a given dose were on the average twofold lower than during the nonfebrile phase, owing to impaired absorption of acetylsalicylic acid. It is suggested that despite the difficulty in achieving therapeutic serum concentrations of salicylate during the febrile phase of Kawasaki disease with a dose as high as 100 mg/kg/day, this dose is potentially capable of preventing the associated coronary disease.

(JAMA 1985;254:767-769)

×